Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS.
Shitara K, Yokota T, Takahari D, Shibata T, Ura T, Utsunomiya S, Inaba Y, Yamaura H, Sato Y, Najima M, Kawai H, Tajika M, Sawaki A, Yatabe Y, Muro K.
Shitara K, et al. Among authors: ura t.
Invest New Drugs. 2011 Aug;29(4):688-93. doi: 10.1007/s10637-009-9382-x. Epub 2010 Jan 14.
Invest New Drugs. 2011.
PMID: 20072801
Clinical Trial.